Search

A 37-year-old man developed cerebral venous thrombosis (CVT) after misusing cyproterone and ethinylestradiol for hair growth. He had been using a homemade topical solution of oral contraceptive pills containing cyproterone and ethinylestradiol for 3 months. The man presented with a sudden, intense right-sided headache, and a CT venogram confirmed CVT. Treatment with cyproterone and ethinylestradiol was stopped, and he was given anticoagulation therapy, leading to improvement. [Extracted from the article]

A 58-year-old woman with paroxysmal nocturnal haemoglobinuria (PNH) experienced lack of efficacy during treatment with heparin for PNH-associated thrombosis. She presented to the emergency department with muscle weakness, altered behavior, headache, abdominal pain, and dark-colored urine. Further investigations revealed significant thrombosis in various parts of her body. Despite receiving heparin and endovascular mechanical thrombectomy, she passed away a few days later due to PNH-related thrombosis, indicating a lack of efficacy with heparin. [Extracted from the article]

A case report published in Reactions Weekly describes a 35-year-old woman who experienced a lack of efficacy while being treated with acetazolamide for idiopathic intracranial hypertension. The woman presented with symptoms such as headache, tinnitus, and papilloedema, and lumbar puncture revealed increased cerebrospinal fluid pressure. Despite receiving acetazolamide, the patient's papilloedema persisted, indicating that the medication was not effective. Further investigations revealed bilateral transverse sinus stenosis and a dural arteriovenous fistula, which were subsequently treated. The patient showed improvement after receiving a sinus stent. [Extracted from the article]

A 24-year-old woman experienced persistent pulsatile tinnitus while being treated with warfarin for cerebral venous thrombosis. The woman had a history of major depression disorder and had previously undergone surgery to address the severity of her symptoms. Despite the resolution of her initial symptoms, the woman continued to experience pulsatile tinnitus, which was attributed to changes in blood viscosity caused by warfarin. This case highlights the persistence of tinnitus as a potential side effect of warfarin treatment. [Extracted from the article]

A 64-year-old woman with diffuse large B-cell lymphoma of the central nervous system experienced venous thrombotic events while undergoing treatment with cytarabine, dexamethasone, methotrexate, and rituximab. She also showed lack of efficacy during anticoagulant therapy with edoxaban. The woman had a history of dyslipidemia, myofascial pain syndrome, hypersensitivity, and autoimmune thyroiditis. Despite starting chemotherapy and showing initial improvement, she developed venous thrombotic events and ultimately died within three months. [Extracted from the article]

In a retrospective study of 252 children with acute lymphoblastic leukemia (ALL), eight cases were identified where the children developed cerebral venous sinus thrombosis (CVST) during treatment with pegasparaginase. The children ranged in age from 4 to 12 years and experienced symptoms such as paroxysmal headache, vomiting, seizures, blurred vision, and staring. Brain MRI confirmed the diagnosis of CVST, and the children were treated with medications such as warfarin, rivaroxaban, and low-molecular-weight heparin (LMWH), along with symptomatic treatments. This study highlights the potential risk of CVST associated with pegasparaginase therapy in children with ALL. [Extracted from the article]

A 44-year-old woman experienced thrombocytopenia while being treated with paracetamol and omeprazole. She was admitted to the hospital for acute abdominal pain and was found to have low platelet count. The worsening thrombocytopenia was suspected to be a result of the medications. The woman developed cerebral venous sinus thrombosis and eosinophilic granulomatosis with polyangiitis, and despite receiving medical treatment, she passed away. Her cause of death was determined to be cerebral venous sinus thrombosis with thrombocytopenia and eosinophilic granulomatosis with polyangiitis. [Extracted from the article]

In a case series of 5 patients, two young girls experienced adverse reactions during treatment with antibiotics for group A streptococcus (GAS). A 3-year-old girl developed a rash while receiving ceftriaxone, which was discontinued and she recovered without complications. A 5-year-old girl exhibited a lack of efficacy while receiving cefotaxime, clindamycin, and linezolid, and unfortunately, she died due to irreversible brain injury. These cases highlight the potential risks and limitations of antibacterial therapy for GAS infections. [Extracted from the article]

A case series was conducted on three patients who developed skin reactions while being treated with oxcarbazepine for seizure or trigeminal neuralgia. The first patient, a 52-year-old woman, experienced red and itchy lesions on her neck, face, trunk, and limbs. The second patient, a 61-year-old woman, had sudden onset red and itchy lesions on her thighs, trunk, and upper limbs. The third patient, a 20-year-old man, developed red and itchy lesions on his legs and trunk. In all cases, the patients' treatment with oxcarbazepine was stopped and they received other medications for their skin reactions, resulting in improvement. [Extracted from the article]

A case series described three women between the ages of 19 and 43 who developed cerebral venous sinus thrombosis (CVST) or vaccine-induced immune thrombotic thrombocytopenia (VITT) after receiving the AZD-1222 vaccine for COVID-19. One woman also exhibited lack of efficacy during treatment with immune-globulin and plasma for CVST. The patients experienced symptoms such as hemiparesis, headache, nausea, and vomiting, and were diagnosed with CVST through imaging tests. Unfortunately, all three women experienced brain death despite medical interventions. These cases highlight potential complications associated with the AZD-1222 vaccine. [Extracted from the article]

A 44-year-old woman developed cerebral venous sinus thrombosis (CVST) while being treated with ribociclib for metastatic carcinoma. The woman had a history of early-stage breast cancer and had undergone various treatments in the past. After starting ribociclib, she experienced increasing headaches and was diagnosed with CVST. She was treated with anticoagulation therapy and her condition remained stable with no bleeding. [Extracted from the article]

A 25-year-old woman developed cerebral venous sinus thrombosis (CVST) while taking desogestrel for abnormal uterine bleeding. She presented with loss of consciousness, severe headache, vomiting, seizures, and altered sensorium. Diagnostic tests confirmed CVST, and she was treated with enoxaparin, levetiracetam, mannitol, mecobalamin, folic acid, and warfarin. After 26 days in the hospital, she was discharged with no residual neurologic dysfunction. [Extracted from the article]

A 23-year-old man experienced a lack of efficacy during treatment for atypical streptococcal meningitis with ceftriaxone and dexamethasone. He presented with symptoms such as vomiting, altered consciousness, cranial nerve palsy, and meningeal signs. Neuroimaging revealed various complications, including tonsillar herniation and arterial subcortical infarcts. Despite receiving antibiotics and dexamethasone, his neurological state did not improve, and he ultimately experienced brainstem death. The case highlights the lack of effectiveness of ceftriaxone and dexamethasone in this particular situation. [Extracted from the article]

A 32-year-old man experienced a left arm contusion and left foot hematoma after overdosing on warfarin, which he was taking for dural sinus venous thrombosis. The man had a history of alcoholism and tobacco use but had stopped two years ago after his diagnosis. He received vitamin K therapy to reverse the anticoagulation and was prescribed various medications for his symptoms. Despite being advised to undergo surgery for the hematoma, he declined due to financial constraints and was discharged from the hospital. He was prescribed rivaroxaban, chymotrypsin, and amoxicillin/clavulanic-acid for five days and was recommended to have a follow-up after a month. [Extracted from the article]

A 17-year-old girl developed verruca vulgaris, a type of wart, while being treated with secukinumab for netherton syndrome. The girl had previously received various medications and therapies for her condition, including emollients, corticosteroids, and immune-globulin. Despite minimal response to acitretin therapy, she showed significant improvement after receiving secukinumab. However, after four doses, she developed verruca vulgaris as a side effect of the treatment. Fortunately, the warts resolved on their own within two months without any intervention. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 40-year-old woman developed cerebral venous sinus thrombosis and liver enzyme elevation during treatment with eltrombopag for immune thrombocytopenia [route and outcomes not stated; times to reactions onset stated]. [Extracted from the article]

Due a fall on day 12, analyses showed platelet count of 36 x 10 SP 9 sp /L owing to thrombocytopenia; Imaging studies revealed presence of cerebral venous sinus thrombosis, along with small cerebral bleeds and a pulmonary embolus. However, 12 days post vaccination, she developed headaches and diplopia 12 days post vaccination. Patient 3: The 61-year-old woman, received vaccination with Ad26.COV2-S. However, she developed extensive portal vein thrombosis and was found to have severe thrombocytopenia with a platelet count of 19 × 10 SP 9 sp /L post vaccination. [Extracted from the article]

Cranial magnetic resonance imaging (MRI) revealed acute multiple infarcts in the right cerebellar hemisphere and left temporal lobe. Cranial contrast-enhanced MRI revealed a cord-like enhanced signals in the left temporal lobe and a strong signal in the left sigmoid sinus. Hem coagulase induced cerebral venous sinus thrombosis in patients with uterine fibroids surgery. [Extracted from the article]

MRI brain showed abnormal signal in the superior sagittal, left transverse and sigmoid sinus, indicating CVST. Subsequent CT-venogram confirmed a diagnosis of CVST. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 52-year-old woman developed cerebral venous sinus thrombosis (CVST) following an administration of tozinameran vaccination [ I route and dosage not stated i ] The woman, who presented to emergency department due to persistent gradual onset headache from a few days, treated with unspecified NSAIDs and antibiotics for presumed ear/sinus infection. [Extracted from the article]

A follow-up MRI done after 15 days of the initial MRI showed partial recanalisation of the thrombosed sinuses along with the aging of the bilateral frontal haemorrhagic venous infarctions, best appreciated at T1 SE. Case 1: The 9-year-old boy with leukaemia was receiving chemotherapy with cytarabine [ARA C], hydrocortisone, intrathecal methotrexate, oral prednisone, IV asparaginase [L-asparaginase], IV doxorubicin and IV vincristine. Case 3: The 5-year-old boy with ALL was receiving chemotherapy with cytarabine [ARA C], hydrocortisone, intrathecal methotrexate, oral prednisone, IV asparaginase [L-asparaginase], IV doxorubicin and IV vincristine. [Extracted from the article]

Radiological testing indicated left transverse and sigmoid sinus thrombosis with no other intracranial complications. A rare cause of headache-cerebral sinus venous thrombosis after COVID-19 vaccination. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 58-year-old man developed cerebral sinus venous thrombosis following COVID-19 vaccination with AZD-1222. [Extracted from the article]